Apr 28, 2025
Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
Feb 11, 2025
Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin
Jun 26, 2024
Oramed Letter to Shareholders
Jun 26, 2024
Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock
Feb 20, 2024
Oramed Letter to Shareholders
Jan 27, 2021
Oramed Issues Letter to Shareholders
Jan 07, 2021
Oramed to Present at H.C. Wainwright BioConnect 2021 Conference
Dec 23, 2020
Oramed Reports Positive First in Human Data from Oral Leptin Study
Dec 02, 2020
Oramed Initiates Phase 2 NASH Trial of Oral Insulin
Nov 24, 2020
Oramed Initiates Phase 3 Trial of Oral Insulin
Nov 12, 2020
Nobel Laureate, Oramed SAB member Prof. Avram Hershko and Oramed CSO Dr. Miriam Kidron to be Featured on Biotalknology Webinar "Oral Delivery of Therapeutic Proteins - Oramed Story" on November 18, 2020
Nov 10, 2020
Oramed to Present at H.C. Wainwright 6th Annual Israel Conference
Oct 28, 2020
Oramed to Present Phase 2b Oral Insulin Data at American Association of Pharmaceutical Scientists 2020 PharmSci 360 Conference
Oct 27, 2020
Oramed CEO Nadav Kidron & Premas Biotech to Host Webinar "The Journey of Oral Insulin: Oramed Story" on Wednesday October 28, 2020
Oct 16, 2020
Oramed Issues Shareholder Update on Pivotal Phase 3 Oral Insulin Studies: Protocols Submitted to FDA
Sep 21, 2020
Oramed Pharmaceuticals to Present at the European Association for the Study of Diabetes (EASD) Annual Meeting
Sep 15, 2020
Oramed's Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients
Sep 03, 2020
Oramed to Present at H.C. Wainwright Global Investment Conference
Jul 15, 2020
Oramed Reports Positive End of Phase 2 Meeting With the FDA for Oral Insulin
Jun 15, 2020
Oramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral Insulin